Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma

Immune checkpoint inhibitors (ICI) are a standard in cancer therapy, but few patients respond to the treatment. The aim of the present study was the determination of immunological markers for monitoring response to ICI. The present study included 74 patients receiving ICI in subsequent [group 1; non...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2022-09, Vol.24 (3), Article 557
Main Authors: Musaelyan, Aram A, Lapin, Sergey V, Urtenova, Margarita A, Odintsova, Svetlana V, Chistyakov, Ivan V, Ulitin, Andrey M, Akopov, Andrey L, Orlov, Sergey V
Format: Article
Language:English
Subjects:
Antibodies
Biological markers
Biomarkers
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Cloning
Cytokines
Disease
Dosage and administration
Drug therapy
Health aspects
Immune response
Immunology
Immunotherapy
Lung cancer
Lung cancer, Non-small cell
Melanoma
Metastasis
Methods
Monoclonal antibodies
Patients
Physiological aspects
Receptor antibodies
Test systems
Thyroid gland
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICI) are a standard in cancer therapy, but few patients respond to the treatment. The aim of the present study was the determination of immunological markers for monitoring response to ICI. The present study included 74 patients receiving ICI in subsequent [group 1; non-small cell lung cancer (NSCLC)] and first-line setting (group 2; melanoma) and 30 patients with NSCLC receiving first-line chemotherapy. In groups 1 and 2 [beta]-2 microglobulin (B2-MG), neopterin (NPT), IL-6, IL-18, HLA-DRB1 and autoantibodies were assessed after two months of ICI, and before the start of next administration in group 3. In group 1 low level of B2-MG (P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2022.11495